| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2407829 | Vaccine | 2008 | 14 Pages |
Abstract
The need to enhance the immunogenicity of purified subunit antigens has prompted the development of new adjuvants. The adjuvant emulsion MF59™ has been tested in animals in combination with different antigens and finally evaluated in humans. It was licensed after the successful outcome of preclinical and clinical testing.This paper summarizes the main characteristics of the MF59™ adjuvant, including animal testing, clinical experience with various vaccines, and information from current postmarketing surveillance data.This review supports the hypothesis that MF59™ is a safe adjuvant for human use.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Viola Schultze, Vicente D’Agosto, Andreas Wack, Deborah Novicki, Juergen Zorn, Renald Hennig,